Drugs / Imidafenacin
Imidafenacin
also known as
KRP-197 · ONO-8025 · Imidafenacina · Imidafenacine · KRP-197/ONO-8025 · Staybla · Uritos
Small molecule targets CHRM3 via inhibition
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00212706 | Oct 2001 → Nov 2002 | overactive bladder | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03575702 | Jul 2016 → Aug 2017 | overactive bladder | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT00512785 | Aug 2007 → May 2009 | overactive bladder | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00212732 | Oct 2003 → Apr 2006 | overactive bladder | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02294396 | Oct 2014 → Sep 2016 | overactive bladder | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT01578304 | Dec 2010 → Oct 2011 | overactive bladder | LG Life Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-02-17 | Upsher-Smith Laboratories | Regulatory Sawai Receives Approvals for 15 Generic Drugs with 31 Strengths upsher-smith.com ↗
Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 15 generic drugs with 31 strengths. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-17 | Upsher-Smith Laboratories | Sawai Receives Approvals for 15 Generic Drugs with 31 Strengths upsher-smith.com ↗ |
| 2017-03-28 | Synmosa Biopharma Corp. | Synmosa and Kyorin announced License Agreement of Imidafenacin- Patented New Drug for OAB com.tw ↗ |
| 2016-10-04 | Eisai Inc. | LAUNCH OF URITOS® TABLETS FOR OVERACTIVE BLADDER IN THAILAND eisai.com ↗ |
| 2011-11-08 | Daiichi Sankyo | Daiichi Sankyo Brasil and Kyorin Pharmaceutical Reach Agreement in Brazil for Activities Related to the Development and Marketing of Imidafenacin daiichisankyo.com ↗ |
| 2009-09-29 | Eisai Inc. | KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries eisai.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imidafenacin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01578304 ↗ |
| Known as | Imidafenacina | ChEMBL registry synonym — accepted as the source's own label CHEMBL53366 ↗ |
| Known as | Imidafenacine | ChEMBL registry synonym — accepted as the source's own label CHEMBL53366 ↗ |
| Known as | KRP-197 | “ONO-8025 (KRP-197)” NCT00212732 ↗1“ONO-8025 (KRP-197)” NCT00212706 ↗ |
| Known as | KRP-197/ONO-8025 | “imidafenacin, KRP-197/ONO-8025” NCT00512785 ↗ |
| Known as | ONO-8025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00212732 ↗ |
| Known as | Staybla | ChEMBL registry synonym — accepted as the source's own label CHEMBL53366 ↗ |
| Known as | Uritos | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03575702 ↗ |
| Action | Inhibit | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL53366 ↗ |
| Modality | Small molecule | — CHEMBL53366 ↗ |
| Route | Oral | “12 weeks oral administration of Imidafenacin 0.1mg b.i.d versus Fesoterodine 4mg once daily” NCT01578304 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL53366 ↗ |